Illumina Target of Unusually Large Options Trading (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) saw some unusual options trading activity on Monday. Stock investors bought 7,176 call options on the stock. This represents an increase of 107% compared to the average daily volume of 3,471 call options.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Golden State Wealth Management LLC acquired a new position in Illumina in the fourth quarter valued at $32,000. Fourth Dimension Wealth LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the 4th quarter valued at about $45,000. Assetmark Inc. boosted its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. acquired a new stake in Illumina during the fourth quarter worth approximately $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $80.30 on Wednesday. The stock has a market cap of $12.71 billion, a price-to-earnings ratio of -10.46, a P/E/G ratio of 1.60 and a beta of 1.35. Illumina has a twelve month low of $68.70 and a twelve month high of $156.66. The company’s fifty day moving average is $78.77 and its 200 day moving average is $112.48. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business’s revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.98 EPS. Sell-side analysts forecast that Illumina will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ILMN shares. Robert W. Baird reduced their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Citigroup dropped their price objective on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Monday, April 7th. Canaccord Genuity Group decreased their target price on Illumina from $92.00 to $87.00 and set a “hold” rating on the stock in a research report on Monday. Finally, Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $130.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.